Sort
10,766 grants matching “checkpoint inhibitor”
Development Therapeutics Branch Clinical Trials
$263,920Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Targeting EZH2 in CARM1-expressing epithelial ovarian cancer
$263,785Rugang Zhang · Wistar Institute · R01 · FY2021 · CA
Targeting ROS enzymes in myeloid-derived suppressor cell to enhance immunotherapy
$263,733Tracy W Liu · West Virginia University · P20 · FY2022 · GM
Project 3: Improving therapeutic approaches for breast cancer brain metastases
$263,646Jean Zhao · Dana-Farber Cancer Inst · P50 · FY2022 · CA
Project 2: Targeting Neoantigens for Lung Cancer Immunotherapy
$263,434Stanley R Riddell · Fred Hutchinson Cancer Research Center · P50 · FY2021 · CA
Regulation of Genomic Instability in Early Breast Cancer
$263,333Thea D Tlsty · University Of California, San Francisco · R01 · FY2006 · CA
Aurora-A/BTAK/STK15 Oncoprotein in Mitotic Spindle Assembly and Checkpoint Respon
$263,309Subrata Sen · University Of Tx Md Anderson Can Ctr · R01 · FY2008 · CA
Project 1: Targeting the Neutrophil Lineage To Enhance Immune Checkpoint Inhibitor Efficacy in NSCLC
$263,281A. McGarry Houghton · Fred Hutchinson Cancer Research Center · P50 · FY2021 · CA
Targeting SOCS1 and RASA2 to Engineer More Potent Adoptive T Cell Therapies for Cancer Treatment.
$263,267Julia C Carnevale · University Of California, San Francisco · K08 · FY2024 · CA
Targeting SOCS1 and RASA2 to Engineer More Potent Adoptive T Cell Therapies for Cancer Treatment.
$263,267Julia C Carnevale · University Of California, San Francisco · K08 · FY2022 · CA
Targeting SOCS1 and RASA2 to Engineer More Potent Adoptive T Cell Therapies for Cancer Treatment.
$263,267Julia C Carnevale · University Of California, San Francisco · K08 · FY2023 · CA
Determining the impact of ancestry on oropharyngeal cancer biology and treatment response.
$263,164Vlad C Sandulache · Baylor College Of Medicine · R21 · FY2023 · DE
Multi-strain, live biotherapeutics as adjuncts to checkpoint inhibitor therapy
$263,086Hyungsoo Kim · Sanford Burnham Prebys Medical Discovery Institute · R21 · FY2021 · CA
The role of gut microbe-derived choline metabolites in driving the pro-inflammatory macrophage phenotype and restricting pancreatic cancer
$262,871Rahul Suresh Shinde · Wistar Institute · R21 · FY2021 · CA
MECHANISMS OF DNA DAMAGE TRIGGERED S PHASE CHECKPOINTS
$262,795State University Of New York At Buffalo · R01 · FY2002 · CA
Project 3
$262,762Michelle Krogsgaard · New York University School Of Medicine · P50 · FY2019 · CA
Exploiting Therapeutic Vulnerabilities
$262,672William A Weiss · Children'S Hospital Of Los Angeles · P01 · FY2019 · CA
(PQ8) Predictive biomarkers for the onset of immune-related adverse events associated with PD-1 blockade
$262,440Adam Mor · Columbia University Health Sciences · R21 · FY2019 · CA
Dissecting histone regulation of the DNA-damage checkpoint in proliferating cells
$262,400Amanda A Amodeo · Dartmouth College · P20 · FY2022 · GM
Dissecting histone regulation of the DNA-damage checkpoint in proliferating cells
$262,400Amanda A Amodeo · Dartmouth College · P20 · FY2021 · GM
Selective histone deacetylase inhibition with entinostat to enhance the anti-tumor immune response to immune checkpoint inhibition in urothelial cancer
$262,296Tracy L Rose · Univ Of North Carolina Chapel Hill · K08 · FY2020 · CA
Selective histone deacetylase inhibition with entinostat to enhance the anti-tumor immune response to immune checkpoint inhibition in urothelial cancer
$262,296Tracy L Rose · Univ Of North Carolina Chapel Hill · K08 · FY2021 · CA
Selective histone deacetylase inhibition with entinostat to enhance the anti-tumor immune response to immune checkpoint inhibition in urothelial cancer
$262,296Tracy L Rose · Univ Of North Carolina Chapel Hill · K08 · FY2022 · CA
Suppression of translocations by RecQ-like DNA helicases
$261,954Kristina Schmidt · University Of South Florida · R01 · FY2010 · GM
"Optimizing synthetic lethality in high-grade serous ovarian cancer"
$261,716Fiona Simpkins · Johns Hopkins University · P50 · FY2020 · CA